ArticleFrontiers in pharmacology2026
Extracellular vesicle-mediated preconditioning of osteoblasts by ER+ breast cancer cells: implications for the bone metastatic niche.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer metastasis to bone most commonly occurs in late-stage disease and remains a major contributor to morbidity, reduced quality of life, and mortality, particularly in estrogen receptor-positive (ER+) tumors. Intercellular communication between tumor cells and bone-resident cells plays a critical role in promoting tumor invasion and development of metastatic bone lesions. Historically, tumor-bone interactions have been viewed largely through the lens of soluble factor-mediated signaling, particularly in the context of osteoclast-driven bone resorption and osteolytic lesion formation. However, the majority of bone metastases exhibit a mixed lytic and sclerotic phenotype, reflecting the combined involvement of osteoclast- and osteoblast-mediated remodeling. Here, we investigate how ER+ breast cancer-derived extracellular vesicle-enriched conditioned media influence osteoblast behavior and signaling
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.